相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins
Harald Hefter et al.
FRONTIERS IN NEUROLOGY (2021)
Reply to Comment on Re-Visiting Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 2019, 11, 491
Steven Bellows et al.
TOXINS (2020)
Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy
Uwe Walter et al.
NEUROLOGY (2020)
Immunogenicity Associated with Botulinum Toxin Treatment
Steven Bellows et al.
TOXINS (2019)
High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy
Philipp Albrecht et al.
NEUROLOGY (2019)
Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia
Harald Hefter et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study
Marek Moll et al.
PARKINSONISM & RELATED DISORDERS (2018)
Clinical Practice: evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin
Maria Fiorella Contarino et al.
FRONTIERS IN NEUROLOGY (2017)
Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis
Margherita Fabbri et al.
NEUROTOXICITY RESEARCH (2016)
Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes
H. A. Jinnah et al.
JOURNAL OF NEUROLOGY (2016)
The role of polymyography in the treatment of cervical dystonia
Roberto Erro et al.
JOURNAL OF NEUROLOGY (2016)
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache Report of the Guideline Development Subcommittee of the American Academy of Neurology
David M. Simpson et al.
NEUROLOGY (2016)
High Botulinum Toxin-Neutralizing Antibody Prevalence Under Long-Term Cervical Dystonia Treatment
Harald Hefter et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2016)
Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia
Joaquim J. Ferreira et al.
PARKINSONISM & RELATED DISORDERS (2015)
Botulinum Neurotoxins: Qualitative and Quantitative Analysis Using the Mouse Phrenic Nerve Hemidiaphragm Assay (MPN)
Hans Bigalke et al.
TOXINS (2015)
Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins - a single cohort 4-year follow-up study
Harald Hefter et al.
BMJ OPEN (2012)
Neutralizing Antibodies and Secondary Therapy Failure After Treatment With Botulinum Toxin Type A: Much Ado About Nothing?
Oliver Lange et al.
CLINICAL NEUROPHARMACOLOGY (2009)
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay
Mitchell F. Brin et al.
MOVEMENT DISORDERS (2008)
Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A
G. Kranz et al.
NEUROLOGY (2008)
Long-term botulinum toxin efficacy, safety, and immunogenicity
NI Mejia et al.
MOVEMENT DISORDERS (2005)
Craniocervical dystonia questionnaire (CDQ-24):: development and validation of a disease-specific quality of life instrument
J Müller et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Botulinum toxin antibody type A titres after cessation of botulinurn toxin therapy
D Dressler et al.
MOVEMENT DISORDERS (2002)
分享论文
